Across TCGA pan-cancer cohorts, IMPDH1P2 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated IMPDH1P2 data layer compared with 16 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher IMPDH1P2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IMPDH1P2 expression acts as an unfavorable survival marker.

SARC are the cancer types where IMPDH1P2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	OS	Median	All	0.143	0.745	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: IMPDH1P2 tumor-vs-normal RNA expression · all IMPDH1P2 data types